Chester County News and Community Website
PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) has announced encouraging updates from the ongoing Phase 1/2 upliFT-D clinical trial for PBFT02, a one-time gene therapy for frontotemporal dementia (FTD) …
Passage Bio Reports Progress in Gene Therapy for Frontotemporal Dementia Read More
PHILADELPHIA, PA — Latus Bio, Inc. has announced a significant advancement in the field of gene therapy with the publication of its latest research in Nature Communications. The study, led …
Latus Bio Unveils Breakthrough in Gene Therapy for Neurodegenerative Diseases Read More
PHILADELPHIA, PA — Last week, VintaBio presented promising new data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, spotlighting its proprietary VintaProcess™. This innovative platform …
VintaBio Showcases Breakthrough Gene Therapy Manufacturing Platform Read More PHILADELPHIA, PA — Latus Bio, Inc. has unveiled groundbreaking research on a novel adeno-associated virus (AAV) capsid variant, AAV-Ep+, which shows significant promise for advancing gene therapy applications. Published in …
Latus Bio Announces Breakthrough in Gene Therapy with AAV-Ep+ Capsid Read More PHILADELPHIA, PA — Latus Bio Inc. (Latus) will showcase its groundbreaking progress in AAV capsid variants—AAV-DB-3 and AAV-Ep+—at the 2025 American Society for Gene and Cell Therapy (ASGCT) Annual Meeting …
Latus Bio to Spotlight Advances in Gene Therapy at ASGCT Annual Meeting Read More
SPRING HOUSE, PA and WATERTOWN, MA — ChromaTan Inc. and Landmark Bio PBLLC have been awarded a grant from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) to support the …
ChromaTan and Landmark Bio Receive NIIMBL Grant to Advance AAV Gene Therapy Manufacturing Read More
WEST CHESTER, PA — Pathways Neuro Pharma Inc. has announced a significant pivot in its development pipeline, prioritizing rare pediatric neurological disorders, with Juvenile Parkinson’s Disease (JPD) leading the charge. This …
Pathways Neuro Pharma Targets Rare Pediatric Neurological Disorders with Pioneering Gene Therapy Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced the completion of dosing in the Phase 2 portion of its ArMaDa clinical trial for OCU410. This novel multifunctional modifier gene therapy …
Breakthrough Gene Therapy OCU410 Could Save Millions from Vision Loss – Phase 2 Milestone Achieved! Read More
KING OF PRUSSIA, PA — CSL (ASX: CSL; USOTC: CSLLY) has unveiled four-year results from its pivotal HOPE-B study, demonstrating the long-term durability and safety of HEMGENIX® (etranacogene dezaparvovec-drlb), the …
CSL Reports Promising Four-Year Data on Gene Therapy for Hemophilia B Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has reached a significant milestone in the development of its gene-agnostic therapy, OCU400, as the European Commission has delivered a positive opinion designating it …
Ocugen’s OCU400 Receives ATMP Classification from European Commission, Advancing Retinitis Pigmentosa Treatment Read More